Metabolic Reprogramming in Cancer
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 842
Special Issue Editor
Interests: cancer; mitochondrial metabolism; metabolic reprogramming; hybrid metabolic status; transmitochondrial cybrids and fatty acid oxidation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recent developments in cancer metabolism suggest that most tumor mitochondria are not dysfunctional, but are reprogrammed to have their ability to carry out oxidative phosphorylation (OXPHOS). Metabolic reprogramming is an effective way for cancer cells to reorganize their metabolic pathways and to effectively use all of the available resources for its high energy demand. As mitochondria have energy sources other than glucose, like fatty acid and glutamine, metabolic reprogramming will allow cancer cells to utilize such alternative pathways as an energy source. Aggressively metastatic cancer cells and tumour initiating cancer stem cells can acquire a stable “hybrid metabolic phenotype” with a high glycolytic and OXPHOS activity. A hybrid phenotype allows cancer cells to utilize multiple fuels for energy and to maintain moderate reactive oxygen species (ROS) signalling. Extensive crosstalk between the mitochondria and the nucleus also influences many tumour and cellular activities. Importantly, several proto-oncogenes and tumor suppressors are actively involved in the regulation of metabolism. Many such nuclear DNA encoded proteins are known to be located inside the mitochondria, but with unknown functional significance. Contrarily, mitochondrial metabolism is also known to regulate the activation of oncoproteins through transcriptional and post-translational regulations. Recently, the metabolically targeting of cancer cells has been receiving increased attention in oncology. The repurposing of established metabolic targets, like the metformin, is now being considered for cancer prevention or therapy. Understanding more mechanisms of mitochondrial reprogramming in cancer can support the development of newer agents to metabolically target cancer subtypes and to repurpose the existing metabolic drugs for cancer therapy.
Dr. Benny Abraham Kaipparettu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
